This prospective study will evaluate the efficacy of Diafert as an adjunct to morphological assessment in predicting embryos' potential to develop to the blastocyst stage on Day 5.
Study Type
OBSERVATIONAL
Enrollment
100
The Diafert output, the G-CSF concentration in FF, will be recorded but will not be used in patient management.
Huntington Reproductive Center
Encino, California, United States
Women's Medical Research Group
Clearwater, Florida, United States
InVia Fertility Specialists
Hoffman Estates, Illinois, United States
Institute for Reproductive Health
Number of Embryos that achieve the blastocyst stage of development at Day 5 as determined by morphological assessment using the SART criteria
The status of each embryo will be assessed by an independent panel of 5 embryologists through visual inspection using the Society for Assisted Reproductive Technology (SART) criteria to determine if each embryo has achieved the blastocyst stage of development or not.
Time frame: Day 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cincinnati, Ohio, United States
Main Line Fertility Center
Bryn Mawr, Pennsylvania, United States
Dallas - Fort Worth Fertility Associates
Dallas, Texas, United States
Houston Fertility Institute
Houston, Texas, United States
Utah Fertiity Center
Pleasant Grove, Utah, United States
Reproductive Care Center
Sandy City, Utah, United States